Chordate Medical

"The PM010 study is progressing well, with approximately 40 percent of the maximum number of patients currently recruited. One of the study's goals is to obtain as broad an overview as possible of different markets and healthcare models, which is why it is important that our new focus market, Switzerland, is also represented in the study. Inselspital in Bern is also an important reference clinic for Neurolite, our Swiss distributor," says Anders Weilandt, CEO of Chordate.

PM010 is an ongoing open clinical post-market surveillance to monitor long-term outcomes and safety of Ozilia® in patients with chronic migraine under routine clinical care. The study is designed to recruit up to 200 patients and is being conducted at 12 clinics across four European countries, with a follow-up period of 12 months. Data from this study will be reported at intervals and also be used to refine recommendations for the clinical treatment regimen.